By Fineline Cube 
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its 2025 interim financial results for the six months ended June 30, 2025. The company posted RMB 1.168 billion in revenue – a 49 % year‑on‑year (YoY) increase – driven largely by domestic sales of its flagship immunotherapy Toripalimab (TUOYI), which grew 42 % YoY to RMB 954 million.
Key Financial Highlights
| Metric | H1 2025 | YoY Change |
|---|---|---|
| Total Revenue | RMB 1.168 billion | +49 % |
| Domestic Sales of Toripalimab | RMB 954 million | +42 % |
| Net Loss | Narrowed significantly vs. H1 2024 | – |
| Cash & Cash Equivalents | RMB 3.49 billion | – |
Capital Raising
- New H‑share placement – Completed under general mandate on 29 Sept 2025.
- Net proceeds – Approximately HK$1.026 billion added to the balance sheet.
Strategic Implications
- Robust top‑line growth underscores the global demand for Toripalimab, a PD‑1 inhibitor approved for melanoma, non‑small‑cell lung cancer and other solid tumors.
- Improvements in profitability reflect cost control measures and an expanding drug pipeline.
- Strong liquidity (RMB 3.49 billion) provides a solid foundation for R&D investment, potential acquisitions, and future capital markets activity.
Forward‑Looking Statements
This release contains forward‑looking statements that are subject to risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech